Compare · ALMS vs NVO
ALMS vs NVO
Side-by-side comparison of Alumis Inc. (ALMS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 212.6x ALMS ($816.7M).
- Over the past year, ALMS is up 36.3% and NVO is down 28.6% - ALMS leads by 64.8 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for ALMS).
- NVO has more recent analyst coverage (25 ratings vs 15 for ALMS).
- Company
- Alumis Inc.
- Novo Nordisk A/S
- Price
- $6.11-3.02%
- $38.82-1.05%
- Market cap
- $816.7M
- $173.66B
- 1M return
- -21.78%
- -10.14%
- 1Y return
- +36.27%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 1
- 4
- Recent ratings
- 15
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ALMS
- Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
- Director Akkaraju Srinivas bought $10,726,255 worth of shares (986,721 units at $10.87) and sold $1,014,028 worth of shares (96,131 units at $10.55) (SEC Form 4)
- Alumis to Participate in Upcoming September Investor Conferences
- Alumis downgraded by Guggenheim
- Alumis upgraded by H.C. Wainwright with a new price target
- Alumis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
- SEC Form 10-Q filed by Alumis Inc.
- Alumis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank